RNA vaccine fights childhood cancers in new trial

NCT ID NCT05660408

Ongoing Disease control Sponsor: University of Florida Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new RNA-lipid particle vaccine for children and young adults (ages 3-25) with recurrent high-grade glioma or osteosarcoma that has spread to the lungs. The vaccine is made from the patient's own tumor material and aims to train the immune system to attack the cancer. The trial will check safety, the right dose, and whether the vaccine activates immune cells.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RNA-lipid particle vaccine (personalized from the patient's tumor)
What this could lead to: If it works, this could point toward a new treatment option for children with hard-to-treat brain tumors or bone cancer that has come back.
What could go wrong: This is an early-phase trial with only 36 participants, so it is too small to prove effectiveness. The vaccine may not work for everyone, and there could be side effects from the immune response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT HIGH GRADE GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer glioma malignant glioma pediatric high-grade glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT HIGH GRADE GLIOMA RECURRENT PULMONARY OSTEOSARCOMA

Contacts and locations

Locations

UF Health

Gainesville, Florida, 32608, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.